仑伐替尼联合经皮肝动脉栓塞化疗在晚期肝癌患者中的应用效果  

Application Effect of Lenvatinib Combined with Percutaneous Hepatic Arterial Chemoembolization in Patients with Advanced Liver Cancer

作　　者：袁齐元 Yuan Qi-yuan(Department of Oncology,Daye Hospital of Traditional Chinese Medicine Daye 435100,Hubei Province,China)

机构地区：[1]湖北省大冶市中医医院肿瘤内科,湖北大冶435100

出　　处：《中外医药研究》2022年第18期18-20,共3页JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH

摘　　要：目的:探讨仑伐替尼联合经皮肝动脉栓塞化疗(TACE)在晚期肝癌患者中的应用效果。方法:选取2018年1月—2021年1月大冶市中医医院收治的晚期肝癌患者60例为研究对象,根据随机数字表法分为对照组与研究组,各30例。对照组给予TACE治疗,研究组在对照组基础上给予仑伐替尼治疗。比较两组患者近期疗效、血清肿瘤标志物[甲胎蛋白(AFP)、癌胚抗原(CEA)、血管内皮生长因子(VEGF)]水平、不良反应发生率。结果:研究组治疗总有效率高于对照组,差异有统计学意义(P=0.032);治疗后,两组患者AFP、CEA、VEGF水平均下降,差异有统计学意义(P<0.05);研究组患者AFP、CEA、VEGF水平均低于对照组,差异有统计学意义(P=0.000)。结论:仑伐替尼联合TACE治疗晚期肝癌效果显著,可有效提高患者短期疗效,改善患者血清肿瘤标志物水平。Objective:To investigate the application effect of lenvatinib combined with transcatheter arterial chemoembolization(TACE)in patients with advanced liver cancer.Methods:From January 2018 to January 2021,60 patients with advanced liver cancer admitted to Daye Hospital of Traditional Chinese Medicine were selected as the research objects.According to the random number table method,they were divided into the control group and the research group,with 30 cases in each group.The control group was given TACE treatment,and the research group was given lenvatinib treatment on the basis of the control group.The short-term efficacy,serum tumor markers[alpha-fetoprotein(AFP),carcinoembryonic antigen(CEA),vascular endothelial growth factor(VEGF)]levels,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the treatment group was higher than that of the control group,and the difference was statistically significant(P=0.032).After treatment,the levels of AFP,CEA,and VEGF in the two groups decreased,and the difference was statistically significant(P<0.05).The levels of AFP,CEA,and VEGF in the study group were lower than those in the control group,and the difference was statistically significant(P=0.000).Conclusion:Lenvatinib combined with TACE has a significant effect in the treatment of advanced liver cancer,which can effectively improve the short-term curative effect of patients and improve the levels of serum tumor markers in patients.

关 键 词：仑伐替尼 经皮肝动脉栓塞化疗 晚期肝癌 近期疗效 肿瘤标志物 

分 类 号：R73[医药卫生—肿瘤]